BioCryst Pharmaceuticals, Inc.
 (BCRX)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • May 8, 2015, 7:00 AM
    • BioCryst Pharmaceuticals (NASDAQ:BCRX): Q1 EPS of -$0.21 beats by $0.04.
    • Revenue of $6.83M (+97.4% Y/Y) beats by $2.53M.
    | May 8, 2015, 7:00 AM
  • May 7, 2015, 5:30 PM
    | May 7, 2015, 5:30 PM | 7 Comments
  • May 1, 2015, 5:36 PM
    • Top gainers, as of 5:15 p.m.: NNVC +16.2%. NYT +4.8%. DO +3.1%. BCRX +2.7%. SRPT +2.6%.
    • Top losers, as of 5:15 p.m.: MACK -3.9%. ITEK -3.8%. BLX -3.7%. SALT -2.0%. DCI -2.0%.
    | May 1, 2015, 5:36 PM | 1 Comment
  • Apr. 21, 2015, 9:42 AM
    • Bristol-Myers Squibb (BMY +1.3%) upgraded to Overweight with $80 (21% upside) by Morgan Stanley.
    • Align Technology (ALGN +4.6%) upgraded to Overweight with a $79 (46% upside) price target by Morgan Stanley.
    • Biocryst Pharmaceuticals (BCRX +4.5%) upgraded to Neutral with $12 (20% upside) by Bank of America.
    • Rosetta Genomics (ROSG -1%) upgraded to Buy with $5.50 (32% upside) price target by Cantor Fitzgerald.
    • Phibro Animal Health (PAHC -2.7%) downgraded to Underweight with $35 (3% upside) price target by Morgan Stanley.
    • Impax Laboratories (IPXL +0.5%) downgraded to Sell with $36 (28% downside risk) price target by UBS.
    | Apr. 21, 2015, 9:42 AM
  • Apr. 1, 2015, 9:13 AM
    | Apr. 1, 2015, 9:13 AM | 1 Comment
  • Mar. 31, 2015, 5:36 PM
    | Mar. 31, 2015, 5:36 PM | 3 Comments
  • Mar. 31, 2015, 9:13 AM
    | Mar. 31, 2015, 9:13 AM | 1 Comment
  • Mar. 31, 2015, 8:31 AM
    • The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response's Biomedical Advanced Research and Development Authority (BARDA) awards BioCryst Pharmaceuticals (NASDAQ:BCRX) a contract for the continued development of BCX4430 for the potential treatment of diseases caused by RNA pathogens, including filoviruses.
    • The base contract of $12.1M will support the manufacturing of BCX4430, while $22.9M in additional development options may be exercised by the government. The scope of the work in the base contract pertains to manufacturing, process improvement and scale-up over an 18-month period. The BCX4430 produced under the contract will be used in clinical trials and non-clinical toxicology studies that will support a New Drug Application (NDA) filing with the FDA for both intravenous and intramuscular formulations of BCX4430.
    • President & CEO Jon P. Stonehouse says, "BCX4430 currently represents the only single drug that has demonstrated a survival benefit in non-human primates infected with Marburg or Ebola viruses. This new BARDA contract provides continuity in the ongoing development of our broad spectrum antiviral, '4430, and moves this program closer to the finish line."
    • BCX4430 is an RNA dependent-RNA polymerase inhibitor that has shown broad-spectrum activity against in vitro against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.
    | Mar. 31, 2015, 8:31 AM
  • Feb. 20, 2015, 7:15 AM
    • The World Health Organization (WHO) approves the use of a 15-minute point-of-care test developed by Corgenix Medical (OTCQB:CONX) to detect the presence of the Ebola virus. The company developed the assay with funding assistance of the Bill & Melinda Gates Foundation and the Paul G. Allen Family Foundation.
    • Procurement and roll-out in Africa will begin in a few weeks pending the completion of administrative procedures with the U.S. FDA.
    • Ebola-related tickers: (NYSE:MRK) (NASDAQ:NLNK) (NYSEMKT:IBIO) (NASDAQ:NVAX) (NYSE:GSK) (NYSE:JNJ) (NASDAQ:TKMR) (NYSEMKT:HEB) (NASDAQ:BCRX) (NASDAQ:SRPT) (NASDAQ:CMRX) (NASDAQ:ABIO) (OTCQB:AEMD) (OTCPK:BVNRY) (NASDAQ:INO) (OTCQX:RHHBY)
    | Feb. 20, 2015, 7:15 AM | 11 Comments
  • Feb. 18, 2015, 8:20 AM
    • BioCryst Pharmaceuticals (BCRX +0.7%) Q4 results: Revenues: $5.4M (-49.1%); R&D Expense: $18.5M (+19.4%); G&A: $2M (+42.9%); Operating Loss: ($15.2M) (-141.3%); Net Loss: ($11.7M) (-116.7%); Loss Per Share: ($0.16) (-77.8%).
    • FY2014 results: Revenues: $13.6M (-21.4%); R&D Expense: $51.8M (+23.6%); G&A: $7.5M (+25.0%); Operating Loss: ($45.8M) (-49.2%); Net Loss: ($45.2M) (-50.2%); Loss Per Share: ($0.68) (-23.6%); Quick Assets: $32.6M (+999%).
    • 2015 Guidance: Cash burn: $65M - 80M; operating expenses: $75M - 95M.
    | Feb. 18, 2015, 8:20 AM
  • Feb. 18, 2015, 6:58 AM
    • BioCryst Pharmaceuticals (NASDAQ:BCRX): Q4 EPS of -$0.16 beats by $0.05.
    • Revenue of $5.45M (-48.4% Y/Y) beats by $1.81M.
    | Feb. 18, 2015, 6:58 AM | 1 Comment
  • Feb. 17, 2015, 5:30 PM
    | Feb. 17, 2015, 5:30 PM | 4 Comments
  • Feb. 11, 2015, 3:38 AM
    • President Obama is expected to announce plans today to withdraw most of the U.S. troops assigned to combat the Ebola outbreak in West Africa, where they had been deployed to assist with supply logistics, construction and training.
    • The return of the troops comes as the number of new infections drops in the region - from 1,000 new suspected, probable and confirmed Ebola cases a week in October to about 150 a week in recent reports.
    • Ebola-related stocks: JNJ, GSK, HEB, BCRX, NLNK, NNVC, INO, TKMR -0.5% AH
    | Feb. 11, 2015, 3:38 AM | 5 Comments
  • Feb. 6, 2015, 5:37 PM
    | Feb. 6, 2015, 5:37 PM
  • Jan. 26, 2015, 7:49 AM
    • The FDA grants Fast Track status to BioCryst Pharmaceuticals' (NASDAQ:BCRX) plasma kallikrein inhibitor BCX4161 for the treatment of hereditary angioedema. The product candidate is currently in Phase 2/3 development. Clinical trial results are expected by the end of this year.
    • Fast Track designation allows for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
    | Jan. 26, 2015, 7:49 AM | 2 Comments
  • Jan. 22, 2015, 12:12 PM
    • Thinly-traded micro cap NanoViricides (NNVC +20.5%) moves up in early trading on higher volume albeit on modest turnover of 230K shares. Before the open, the company announced that it shipped several anti-Ebola nanoviricide drug candidates to an unnamed "hi-security bio-containment facility" for evaluation.
    • The company states that it progressed from design to synthesis of the drug candidates in only four months using its rapid design platform.
    • Related tickers: (TKMR +0.2%)(BCRX -2.9%)(HEB -3.2%)(INO -2.3%)(SRPT -0.4%)(CMRX -1.4%)(ABIO -1.6%)
    | Jan. 22, 2015, 12:12 PM | 1 Comment
Company Description
Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States